Evolus Inc (NASDAQ:EOLS) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,700,000 shares, an increase of 11.8% from the December 15th total of 5,100,000 shares. Based on an average trading volume of 553,500 shares, the short-interest ratio is presently 10.3 days. Approximately 25.6% of the shares of the stock are sold short.
Shares of EOLS traded up $0.28 during mid-day trading on Thursday, hitting $11.12. The company’s stock had a trading volume of 9,188 shares, compared to its average volume of 675,165. The company’s 50-day moving average is $12.19 and its 200-day moving average is $14.93. Evolus has a 52-week low of $10.31 and a 52-week high of $30.25. The firm has a market capitalization of $366.67 million, a price-to-earnings ratio of -6.99 and a beta of 4.24. The company has a current ratio of 3.66, a quick ratio of 3.28 and a debt-to-equity ratio of 4.53.
Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.55. The business had revenue of $13.17 million during the quarter, compared to analysts’ expectations of $5.18 million. As a group, sell-side analysts predict that Evolus will post -3.75 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp lifted its position in shares of Evolus by 21.6% in the 3rd quarter. State Street Corp now owns 230,987 shares of the company’s stock worth $3,608,000 after purchasing an additional 41,046 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Evolus during the 2nd quarter worth approximately $4,167,000. Rhumbline Advisers raised its stake in shares of Evolus by 15.2% during the 3rd quarter. Rhumbline Advisers now owns 14,797 shares of the company’s stock worth $231,000 after acquiring an additional 1,953 shares in the last quarter. Millennium Management LLC raised its stake in shares of Evolus by 36.7% during the 3rd quarter. Millennium Management LLC now owns 170,072 shares of the company’s stock worth $2,656,000 after acquiring an additional 45,653 shares in the last quarter. Finally, HighTower Advisors LLC bought a new position in shares of Evolus during the 2nd quarter worth approximately $175,000. 16.94% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Evolus from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. Leerink Swann started coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price on the stock. Svb Leerink started coverage on shares of Evolus in a report on Tuesday, November 26th. They issued an “outperform” rating and a $25.00 target price on the stock. ValuEngine upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating on shares of Evolus in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $26.36.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Article: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.